Literature DB >> 30270368

Diagnosis of pancreatic cancer via1H NMR metabolomics of human plasma.

Lenka Michálková1, Štěpán Horník, Jan Sýkora, Lucie Habartová, Vladimír Setnička.   

Abstract

Metabolic changes induced by pancreatic cancer were investigated by 1H NMR spectroscopy of plasma samples of patients and healthy controls. The acquired data were submitted to multivariate statistical analysis providing clear discrimination between both groups. The most significant differences were found in levels of 3-hydroxybutyrate and lactate. The obtained results (100% sensitivity, 90% specificity) clearly show the potential of 1H NMR spectroscopy in pancreatic cancer diagnosis. Therefore, the NMR-based metabolomics may contribute to the early diagnosis, prevention and/or therapy of diseases in the future. On the other hand, the number of samples in the presented pilot study is limited and has to be significantly increased in the future in order to obtain solid statistical models and to confirm the current findings.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30270368     DOI: 10.1039/c8an01310a

Source DB:  PubMed          Journal:  Analyst        ISSN: 0003-2654            Impact factor:   4.616


  10 in total

1.  NMR-Based Metabolomics in Cancer Research.

Authors:  Rui Hu; Tao Li; Yunhuang Yang; Yuan Tian; Limin Zhang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Chemotherapeutic efficacy of cucurmosin for pancreatic cancer as an alternative of gemcitabine: a comparative metabolomic study.

Authors:  Binbin Wei; Congfei Wang; Tianhong Teng; Pengfei Guo; Minghuang Chen; Feng Xia; Huili Liu; Jieming Xie; Jianghua Feng; Heguang Huang
Journal:  Gland Surg       Date:  2020-10

3.  Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms.

Authors:  James R Larkin; Susan Anthony; Vanessa A Johanssen; Tianrong Yeo; Megan Sealey; Abi G Yates; Claire Friedemann Smith; Timothy D W Claridge; Brian D Nicholson; Julie-Ann Moreland; Fergus Gleeson; Nicola R Sibson; Daniel C Anthony; Fay Probert
Journal:  Clin Cancer Res       Date:  2022-04-14       Impact factor: 13.801

4.  Discovery of Pancreatic Adenocarcinoma Biomarkers by Untargeted Metabolomics.

Authors:  Ariadna Martín-Blázquez; Cristina Jiménez-Luna; Caridad Díaz; Joaquina Martínez-Galán; Jose Prados; Francisca Vicente; Consolación Melguizo; Olga Genilloud; José Pérez Del Palacio; Octavio Caba
Journal:  Cancers (Basel)       Date:  2020-04-18       Impact factor: 6.639

Review 5.  Metabolomics profile in gastrointestinal cancers: Update and future perspectives.

Authors:  Giulia Nannini; Gaia Meoni; Amedeo Amedei; Leonardo Tenori
Journal:  World J Gastroenterol       Date:  2020-05-28       Impact factor: 5.742

Review 6.  The Potential of Metabolomics in the Diagnosis of Thyroid Cancer.

Authors:  Margarida Coelho; Luis Raposo; Brian J Goodfellow; Luigi Atzori; John Jones; Bruno Manadas
Journal:  Int J Mol Sci       Date:  2020-07-24       Impact factor: 5.923

7.  Time-frequency analysis of serum with proton nuclear magnetic resonance for diagnosis of pancreatic cancer.

Authors:  Asahi Sato; Toshihiko Masui; Akitada Yogo; Takashi Ito; Keiko Hirakawa; Yoshimasa Kanawaku; Kaoru Koike; Shinji Uemoto
Journal:  Sci Rep       Date:  2020-12-14       Impact factor: 4.379

8.  Serum Colorectal Cancer Biomarkers Unraveled by NMR Metabolomics: Past, Present, and Future.

Authors:  Ana M Salmerón; Ana I Tristán; Ana C Abreu; Ignacio Fernández
Journal:  Anal Chem       Date:  2021-11-22       Impact factor: 6.986

Review 9.  Early diagnosis of pancreatic cancer: What strategies to avoid a foretold catastrophe.

Authors:  Valeria Tonini; Manuel Zanni
Journal:  World J Gastroenterol       Date:  2022-08-21       Impact factor: 5.374

Review 10.  Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review.

Authors:  Jinshou Yang; Ruiyuan Xu; Chengcheng Wang; Jiangdong Qiu; Bo Ren; Lei You
Journal:  Cancer Commun (Lond)       Date:  2021-07-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.